Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205894 | 1.00 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL630728 | 1.00 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL630719 | 0.96 | MEN1 (0.46) | MEN1KMT2ANPSR1 | |
| SCHEMBL630773 | 0.92 | MEN1 (0.49) | MEN1KMT2ANPSR1 | |
| SCHEMBL7245273 | 0.92 | MEN1 (0.49) | MEN1KMT2ANPSR1 | |
| SCHEMBL205419 | 0.90 | ALDH1A1 (0.45) | — | |
| SCHEMBL205549 | 0.88 | — | — | |
| SCHEMBL10039818 | 0.88 | — | — | |
| SCHEMBL30578076 | 0.88 | — | — | |
| SCHEMBL8217889 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210379191-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-12-09 | — | — | US | disclosed |
| US-11090389-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200038518-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-06 | — | — | US | disclosed |
| WO-2018071761-A1 | MITOCHONDRIALLY TARGETED PARP INHIBITOR, AND USES THEREOF | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-04-19 | — | — | WO | disclosed |
| CN-103702981-B | Process for producing optically active 2-methylproline derivative | KANEKA CORP. (JP) | 2015-11-25 | — | — | CN | disclosed |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| CN-104220429-A | Non-systemic tgr5 agonists | ARDELYX INC | 2014-12-17 | — | — | CN | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114942-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| WO-2008081910-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-10 | — | — | WO | disclosed |
| EP-1869011-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007063123-A1 | SUBSTITUTED OXINDOL-DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2006110816-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| EP-0210065-A1 | 6-Alkylidene penems | BEECHAM GROUP PLC (GB) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | GLP1R, GPR119, TRHR | MEN1 672/4885KMT2A 1662/4885NPSR1 347/4885 |
| US-20150218146-A1 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | AVPR2, AVPR1B, AVPR1A | MEN1 286/4885KMT2A 3910/4885NPSR1 39/4885 |
| US-11759524-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | PARP1, PARP2, PARP3 | MEN1 2455/4885KMT2A 1643/4885NPSR1 4641/4885 |
| US-20200038518-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | PARP1, PARP2, PARP3 | MEN1 2455/4885KMT2A 1643/4885NPSR1 4641/4885 |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | MEN1 3180/4885KMT2A 904/4885NPSR1 2770/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | MEN1 3097/4885KMT2A 595/4885NPSR1 4421/4885 |
| US-20210379191-A1 | Mitochondrially Targeted PARP Inhibitor, and Uses Thereof | PARP1, PARP2, PARP3 | MEN1 2455/4885KMT2A 1643/4885NPSR1 4641/4885 |
| US-11090389-B2 | Mitochondrially targeted PARP inhibitor, and uses thereof | PARP1, PARP2, PARP3 | MEN1 2455/4885KMT2A 1643/4885NPSR1 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.